Lactobacillus Or Pediococcus Or Leuconostoc Patents (Class 424/93.45)
-
Publication number: 20110038838Abstract: Embodiment include methods for treating cats and dogs with inflammatory bowl disease or inflammatory-like bowl disease or immune mediated hemolytic anemia or atopic dermatitis which are being treated with steroids or immune suppressors which involves the step of administering to the animal a probiotic comprised of P. acidilactici and S. boulardii microorganisms for the purpose of reducing the amount of steroid or immune suppressor required to ameliorate the symptoms of the diseases or conditions.Type: ApplicationFiled: August 11, 2010Publication date: February 17, 2011Applicant: IMAGILIN TECHNOLOGY, LLCInventors: Jhy-Jhu Lin, Gen Kato, Takuo Ishida
-
Publication number: 20110038837Abstract: The present invention is to provide a composition for improving the intestinal microflora for maintaining a good intestinal microflora. The present invention consists of a composition for improving the intestinal microflora characterized by containing L. paracasei KW3110 or its variant as an active component. The composition exhibits an excellent intestinal regulation effect, intestinal environment-improving effect, and intestinal microflora-improving effect, enabling to form healthy microflora in human intestine, when being ingested. Especially, a composition for improving the intestinal microflora of the present invention activates lactic acid bacteria such as Bifidobacterium which are beneficial bacteria among the intestinal microflora, and enables substantively the improvement of the intestinal microflora and the maintenance of a good intestinal microflora. In the present invention, it is particularly preferred that the composition is a composition wherein L.Type: ApplicationFiled: March 14, 2008Publication date: February 17, 2011Inventors: Satoshi Nishida, Toshio Fujii
-
Publication number: 20110038809Abstract: The present invention provides methods for treating or preventing diseases and disorders caused by iron-dependent pathogenic microorganisms, such as bacteria, fungi, and parasites, by applying a gallium compound to an affected area. In particular, the present invention provides methods for treating or preventing dental caries, vaginal infections, skin infections, and so forth. Gallium compounds can be formulated as toothpaste, mouthwash, cream, ointment, gel, solution, eye drops, suppository, and the like. Furthermore, the invention provides methods for controlling microbial growth on environmental surfaces, including those of toothbrush, denture, dental retainer, contact lens, catheter, food stuff, and so forth. In addition, the present invention provides animal feeds which contain gallium compounds that promote the animal growth and prevent the animals from infections as well as protect consumers from post processing infections.Type: ApplicationFiled: October 31, 2006Publication date: February 17, 2011Inventors: Daniel P. Perl, Sharon Moalem
-
Patent number: 7887794Abstract: The invention concerns the isolation of novel properties of lactic acid bacteria stains. Said novel properties are advantageously useful for preventing and treating cancer. More particularly, the invention concerns the use of lactic acid bacteria to facilitate induction of cell apoptosis of a cancer. The invention also concerns the use of lactic acid bacterial strains, such as Lactobacillus acidophilus and Lactobacillus casei in methods and compositions for preventing and treating cancer, in particular colon cancer.Type: GrantFiled: November 27, 2002Date of Patent: February 15, 2011Assignee: Bio-K Plus International, Inc.Inventors: François-Marie Luquet, Cindy Baldwin, Monique Lacroix
-
Patent number: 7883697Abstract: The present invention relates to the use of compositions comprising receptor ligands obtainable by a process comprising fermenting a food material, comprising animal milk or vegetable proteins, with lactic acid bacteria to obtain a fermented food or feed material that comprises ligands of specific adrenoreceptors and/or serotonin receptors. The fermented food or feed material is useful e.g. for reducing and/or stabilizing heart rate in a mammal. It may furthermore be used for treatment and/or relief of erectile dysfunctions and for treatment and/or relief of benign prostate hypertrophy (BPH), in a mammal.Type: GrantFiled: September 5, 2005Date of Patent: February 8, 2011Assignee: CHR-Hansen A/SInventor: Bénédicte Flambard
-
Publication number: 20110027243Abstract: The present invention relates to a composition based on probiotic bacteria and a substance having probiotic properties and the use thereof to prevent and/or treat respiratory pathologies and/or infections and simultaneously improve intestinal functionality, which may be compromised by the therapeutic treatments adopted to resolve said pathological conditions.Type: ApplicationFiled: December 3, 2008Publication date: February 3, 2011Applicant: PROBIOTICAL S.P.A.Inventors: Giovanni Mogna, Gian Paolo Strozzi, Luca Mogna
-
Patent number: 7879363Abstract: The method for increasing lactose tolerance in subjects exhibiting lactose intolerance symptoms implements a protocol where the subjects ingest a gradually increasing amount of lactose containing product over a six week period. At various points during the six week period the subject ingests the lactose containing product once a day and then twice a day. The lactose containing product can be in liquid form, such as for example, milk, and is preferably in a powder form which is taken either by ingesting capsules having the lactose powder or in a granular form mixed with water or other non-lactose containing liquid. At the end of the six week period, the subject's tolerance for lactose containing products is substantially increased, with the potential of eliminating the subject's lactose intolerant behavior indefinitely.Type: GrantFiled: January 11, 2008Date of Patent: February 1, 2011Assignee: Ritter Pharmaceuticals, Inc.Inventor: Andrew J. Ritter
-
Publication number: 20110020304Abstract: This invention relates to a preparation comprising N-acetyl-lactosamine and/or an oligosaccharide containing N-acetyl-lactosamine and a probiotic Lactobacillus sp. The invention extends to nutritional compositions comprising said preparation and to the use of the preparation in the prevention and treatment of pathogenic infections of the gastro-intestinal and upper respiratory tracts.Type: ApplicationFiled: February 24, 2009Publication date: January 27, 2011Applicant: NESTEC S.A.Inventor: Norbert Sprenger
-
Publication number: 20110020303Abstract: The invention relates to the use of probiotics in the manufacture of a composition for enhancing a metabolic profile in a subject. The probiotics are capable of preventing and treating diseases or disorders associated with an abnormal metabolic profile, especially a lipid profile by normalizing the profile. The probiotics are particularly effective in down-regulating levels of lysophosphatiydylcholines (LysoPCs) and ceramides.Type: ApplicationFiled: February 4, 2009Publication date: January 27, 2011Applicant: VALIO, LTD.Inventors: Kajsa Kajander, Riitta Korpela
-
Publication number: 20110014166Abstract: The present invention relates to the novel Sporolactobacillus vineae SL153 strain (Accession No: KCTC 11493BP) having probiotic activity, precisely Sporolactobacillus vineae SL153 having antimicrobial activity against Vibrio genus pathogenic microorganisms and other pathogens. The Sporolactobacillus vineae SL153 strain of the present invention has excellent intestinal adherence and growth inhibitory effect on pathogenic microorganisms including Vibrio genus microorganisms, so that it can be effectively used as a composition for the prevention and treatment of disease caused by pathogenic microorganisms.Type: ApplicationFiled: July 17, 2009Publication date: January 20, 2011Applicant: Korea Research Institute of Bioscience and BiotechnologyInventors: Young-Hyo CHANG, Min-Young Jung, In-Soon Park
-
Publication number: 20110014248Abstract: The present invention relates to a use of an effective amount of at least one probiotic microorganism and/or a fraction thereof and/or a metabolite thereof for preventing and/or treating dandruff disorders of the scalp, as well as a cosmetic process for preventing and/or treating a dandruff condition including the administration a first cosmetic active agent and of at least a second cosmetic active agent, topically, the said first and second cosmetic active agents being formulated in separate compositions, the first cosmetic active agent being chosen from probiotic microorganisms, and mixtures thereof, and the second cosmetic active agent being chosen from antidandruff active agents.Type: ApplicationFiled: March 15, 2010Publication date: January 20, 2011Applicants: L'OREAL, NESTEC SAInventors: Isabelle Castiel, Audrey Gueniche
-
Publication number: 20110014167Abstract: The present invention relates to nutritional compositions comprising Lactobacillus rhamnosus, inulin and soy polysaccharides for the treatment of diarrhoea.Type: ApplicationFiled: July 4, 2008Publication date: January 20, 2011Applicant: N.V. NutriciaInventors: Jacques Bindels, Anna Christina Goedhart
-
Publication number: 20110014168Abstract: Various types of lactic acid bacteria were cultured in the presence of a purine, the amount of the purine consumed and the amount of purine degradation products produced were measured, and several lactic acid bacteria showing remarkable purine-decomposing ability were selected. Lactic acid bacteria that were assessed to have high purine-decomposing ability according to the above-mentioned selection were orally administered to rats reared on purine-containing feed, the general status and serum uric acid level of the rats were measured, and the effect of lactic acid bacteria administration on serum uric acid levels was examined. As a result, lactic acid bacteria that significantly suppress the increase of serum uric acid levels, Lactobacillus gasseri OLL2959 and Lactobacillus oris OLL2779, were found.Type: ApplicationFiled: November 29, 2007Publication date: January 20, 2011Applicant: Meiji Dairies CorporationInventors: Hirosi Tsuboi, Noriko Kaneko, Akina Satou, Yoshinobu Tsuchiya
-
Publication number: 20110014278Abstract: The invention relates to a composition comprising revivable dehydrated micro-organisms. The invention is characterised in that it further comprises particles at least 50% of which have a mean diameter greater than 250 ?m. The invention is applicable, in particular, to human or veterinary pharmaceuticals, to dietetics or to food products.Type: ApplicationFiled: February 6, 2006Publication date: January 20, 2011Applicant: VIRBAC SAInventor: Guy Derrieu
-
Publication number: 20110008303Abstract: Described herein are methods for treating and preventing MRSA/MSSA. The present subject matter deviates from current treatment methods by introducing a controlled decolonization/recolonization method, which eradicates the host surface area of MRSA/MSSA, and colonizes the newly cleared surface area with a nonpathogenic or pathogenic bacteria capable of out-competing MRSA/MSSA.Type: ApplicationFiled: March 12, 2009Publication date: January 13, 2011Applicant: CEDARS-SINAI MEDICAL CENTERInventor: George Y. Liu
-
Patent number: 7867485Abstract: The present invention is directed to a novel method for preventing or treating the development of respiratory allergies. The method comprises prenatal and/or postnatal administration of a therapeutically effective amount of LGG.Type: GrantFiled: October 19, 2007Date of Patent: January 11, 2011Assignee: Mead Johnson Nutrition CompanyInventors: Udo Herz, Nicole Bluemer, Harald Renz, Holger Garn
-
Patent number: 7867486Abstract: The present invention is directed to a novel method for preventing or treating the development of respiratory allergies. The method comprises prenatal and/or postnatal administration of a therapeutically effective amount of LGG.Type: GrantFiled: October 19, 2007Date of Patent: January 11, 2011Assignee: Mead Johnson Nutrition CompanyInventors: Udo Herz, Nicole Bluemer, Harald Renz, Holger Garn
-
Publication number: 20110002900Abstract: The present invention relates in general to medium chain dicarboxylic acids, their derivatives and their uses. In particular, the present invention relates to a composition comprising medium chain dicarboxylic acids and to the use of medium chain dicarboxylic acids and their derivatives for the preparation of products to treat or prevent metabolic disorders. The composition of the present invention can particularly well be used to treat or prevent hyperglycemia, for example diabetes.Type: ApplicationFiled: March 9, 2009Publication date: January 6, 2011Inventors: Geltrude Mingrone, Catherine Mace
-
Publication number: 20110002902Abstract: The present invention provides an inhibitor for blood phosphorus level elevation comprising a lactic acid bacterium as an active ingredient. The inhibitor for blood phosphorus level elevation of the present invention is highly safe, is readily administerable, and can sufficiently inhibit a blood phosphorus level elevation.Type: ApplicationFiled: March 2, 2009Publication date: January 6, 2011Inventors: Masanori Asada, Tadashi Kanaya, Tetsuya Ogawa, Mikiko Shimada, Yumi Uehara
-
Publication number: 20110002901Abstract: It is an object of the present invention to provide a bacterial strain belonging to Lactobacillus brevis subspecies brevis, which has more potent antiallergic activity than the known lactic acid bacteria strains and produces ?-aminobutyric acid (GABA). It is another object of the present invention to provide beverages and foods containing cells of the aforementioned bacterial strain belonging to Lactobacillus brevis subspecies brevis, as well as antiallergic agents containing them as an active ingredient. The present invention provides a bacterial strain belonging to Lactobacillus brevis subspecies brevis, which: is capable of growing in effervescent alcoholic beverages, produces ?-aminobutyric acid (GABA), and has antiallergic activity.Type: ApplicationFiled: August 20, 2007Publication date: January 6, 2011Applicant: SAPPORO BREWERIES LIMITEDInventors: Syuichi Segawa, Yasukazu Nakakita, Yoshihiro Takata, Hisako Yasui
-
Patent number: 7863033Abstract: There has been effort to develop a lactobacillus that would be useful as a probiotic, and to develop a lactobacillus which would colonize and proliferate in lesions of infection, eliminating the causal bacteria. This problem was resolved by developing a Lactobacillus casei species having the following key properties. (1) The species can be grown in the presence of any of one to four amino acids as a nitrogen source necessary for growth. (2) When a growth-promoting culture medium is inoculated with the species and Escherichia coli in the same count and subjected to anaerobic mixed culturing at 37° C., the final count of lactobacilli is 50% or more of the coliform count. (3) Upon cultivation in an appropriate culture medium, the final pH value is 4.0 or below, and the highest acidity is 1.5% or more. (4) The species is resistant to 5% bile salts. (5) The species produces an antibiotic.Type: GrantFiled: July 27, 2004Date of Patent: January 4, 2011Assignee: BHPH Company LimitedInventors: Tadayo Hata, Hitoshi Toshimori, Toshiyuki Maruoka
-
Patent number: 7862809Abstract: A lactic composition containing at least a bacterial strain selected from the group consisting of Lactobacillus acidophilus, Lactobacillus casei and a mixture of Lactobacillus acidophilus and Lactobacillus casei, and a whole broth of the bacterial strain or the mixture of the bacterial strains, is useful for the prevention or treatment of disorders which are angiogenesis dependant. Both the lactic composition and its supernatant can be used for prevention or treatment of angiogenesis dependant disorders. The supernatant of the lactic composition exhibits antiangiogenic properties.Type: GrantFiled: November 15, 2004Date of Patent: January 4, 2011Assignee: Bio-K Plus International, Inc.Inventors: Richard Beliveau, Francois-Marie Luquet
-
Publication number: 20100330040Abstract: Nutritional compositions with health benefits comprising bacterial strains and galactooligosaccharides are disclosed.Type: ApplicationFiled: November 20, 2008Publication date: December 30, 2010Inventors: Jan Knol, Bernd Stahl
-
Publication number: 20100330054Abstract: A preparation for use in the treatment of clostridium difficile or salmonella infection comprising a mixture of galacto-oligosaccharide and matter from cranberry.Type: ApplicationFiled: October 13, 2008Publication date: December 30, 2010Applicant: FAYREFIELD FOODS LIMITEDInventors: Leslie Priest, Vernon Fowler, Kevin Hillman
-
Publication number: 20100330055Abstract: Infection of pathogens is controlled by inducing disease resistance with a method of treating a plant with a composition of an acidic heat-treated solution of microorganisms.Type: ApplicationFiled: July 9, 2010Publication date: December 30, 2010Inventors: Daisuke Igarashi, Taito Takeda, Takashi Ishizaki, Kazuhiko Totsuka
-
Publication number: 20100322964Abstract: The subject of the present invention is a bacterial composition having immunomodulation properties comprising at least one strain selected from the group consisting of Lactobacillus acidophilus PTA-4797, Lactobacillus plantarum PTA-4799, Lactobacillus salivarius PTA-4800, Lactobacillus paracasei PTA-4798, Bifidobacterium bifidum PTA-4801 and Bifidobacterium lactis PTA-4802. An other subject of the invention is an immunomodulation method comprising the step of using the at least one strain selected from the preceding group.Type: ApplicationFiled: May 12, 2010Publication date: December 23, 2010Inventors: Véronique Dennin, Gregory John Leyer, Annick Mercenier, Sophie Nutten, Bruno Pot
-
Publication number: 20100316619Abstract: The present disclosure relates to nutritional compositions comprising a prebiotic component for inhibiting adherence of pathogens in the gastrointestinal tract of a subject and to the prebiotic component, which comprises galactooligosaccharide, polydextrose or any mixture thereof. The nutritional compositions of the present disclosure comprise a fat or lipid source, a protein source, and a carbohydrate source comprising an effective amount of the prebiotic component.Type: ApplicationFiled: July 26, 2010Publication date: December 16, 2010Inventor: Anja Wittke
-
Publication number: 20100316618Abstract: The present invention provides lactic acid bacteria which are suitable for use for dietary products and pharmaceuticals, and which can suppress the increase of blood uric acid level. Various types of lactic acid bacteria were cultured in the presence of a purine, the amount of the purine consumed and the amount of purine degradation products produced were measured, and several lactic acid bacteria showing remarkable purine-decomposing ability were selected. Lactic acid bacteria that were assessed to have high purine-decomposing ability according to the above-mentioned selection were orally administered to rats reared on purine-containing feed, the general status and serum uric acid level of the rats were measured, and the effect of lactic acid bacteria administration on serum uric acid levels was examined. As a result, lactic acid bacteria that significantly suppress the increase of serum uric acid levels, Lactobacillus gasseri OLL2922, were found.Type: ApplicationFiled: November 27, 2008Publication date: December 16, 2010Applicant: MEIJI DAIRIES CORPORATIONInventors: Hiroshi Tsuboi, Noriko Kaneko, Akina Satou, Akinori Kume, katsunori Kimura
-
Patent number: 7846711Abstract: The invention concerns new isolated Lactobacillus cells, which are capable to aggregate Helicobacter pylori under culture conditions of the human digestive tract, in particular of the stomach, and to the uses of such cells.Type: GrantFiled: December 22, 2006Date of Patent: December 7, 2010Assignee: Organobalance GmbHInventors: Mewes Boettner, Eckhard Budde, Christine Lang, Martin Ryser, Markus Veen
-
Publication number: 20100303777Abstract: Delivery of binding molecules, such as antibodies, antibody fragments, single antibody variable domains, soluble receptors, ligands and dominant negative variants, to induce an immunomodulation in a patient is disclosed. More specifically, a medicament which includes micro-organisms which produce the binding molecules is described for the treatment of immune mediated diseases.Type: ApplicationFiled: December 12, 2007Publication date: December 2, 2010Applicant: ActoGeniX N.V.Inventors: An De Creus, Pieter Rottiers
-
Patent number: 7842495Abstract: The invention provides lactic acid bacteria selected from the group consisting of lactobacillus ONRIC b0239 (FERM BP-10064) and lactobacillus ONRIC b0240 (FERM BP-10065), and compositions containing the bacteria, the compositions being capable of stimulating mucosal immunity, and more specifically, the compositions in the form of foods or beverages or pharmaceutical products. The lactic acid bacteria and compositions containing the bacteria are capable of providing excellent mucosal immunostimulation effects and are useful for reinforcing the host defense system.Type: GrantFiled: August 18, 2004Date of Patent: November 30, 2010Assignee: Otsuka Pharmaceutical Co., Ltd.Inventors: Satoko Yamahira, Masamichi Toba, Hiroshi Okamatsu
-
Patent number: 7837989Abstract: The present invention is directed to a novel method for preventing or treating the development of respiratory allergies. The method comprises prenatal and/or postnatal administration of a therapeutically effective amount of LGG.Type: GrantFiled: October 19, 2007Date of Patent: November 23, 2010Assignee: Mead Johnson Nutrition CompanyInventors: Udo Herz, Nicole Bluemer, Harald Renz, Holger Garn
-
Publication number: 20100291051Abstract: The present invention provides an agent for inhibition of alcoholic hepatopathy comprising cells of a strain belonging to Lactobacillus brevis, or treated product thereof as an active ingredient. The agent for inhibition of alcoholic hepatopathy of the present invention is safe for living body and can be used as a component in foods and beverages.Type: ApplicationFiled: January 14, 2009Publication date: November 18, 2010Applicant: SAPPORO BREWERIES LIMITEDInventors: Syuichi Segawa, Yoshihisa Wakita
-
Publication number: 20100285097Abstract: The present invention is related to an intravaginal delivery system for the controlled release of drospirenone and an estrogen, optionally also comprising one or more therapeutically active or a health-promoting substance capable of giving and/or enhancing protection against bacterial and fungal infections, and/or enhancing protection against sexually transmitted diseases. The delivery system consists of one or more compartments, one of each comprising a core and a membrane encasing the core, said core and membrane essentially consisting of a same or different polymer composition, wherein at least one compartment comprises drospirenone ant at least one compartment which may be the same or different from the one comprising drospirenone, comprises an estrogen or a mixture of drospirenone and an estrogen, and wherein the membrane or the surface of the membrane or at least one of the cores comprises said therapeutically active or a health-promoting substance.Type: ApplicationFiled: November 19, 2008Publication date: November 11, 2010Inventors: Christine Talling, Vladimir Hanes, Antti Keinänen, Svante Holmberg, Hannu Nikander
-
Publication number: 20100284972Abstract: Compositions for improving the health of a subject comprise alpha-(1,2)-branched alpha-(1,6) oligodextrans, preferably with an average molecular weight between about 10 kDa and 70 kDa, between about 10% and 50% alpha-(1,2)-osidic side chains, and having at least partial indigestibility in the subject. Methods for improving the health of a subject comprise administering the composition to a subject in an amount effective to improve gut health, or to prevent or treat a gastrointestinal disorder, a cholesterol-related disorder, diabetes, or obesity. Methods for making oligodextrans having controlled size and controlled degree of branching comprise providing alpha-(1,6) oligodextrans having an average molecular weight between 0.5 and 100 kDa and introducing at least 10% alpha-(1,2)-osidic side chains onto the alpha-(1,6) oligodextrans.Type: ApplicationFiled: May 7, 2010Publication date: November 11, 2010Applicant: Tate & Lyle Ingredients France SASInventors: Thierry Naeye, Alexandra Einerhand, Michel Lopez, Susan M. Potter, Magali Remaud-Siméon, Pierre Frédéric Emmanuel Monsan
-
Publication number: 20100284979Abstract: The current invention provides use of a CLA-producing bacterium for the in vivo conversion in the gut of polyunsaturated fatty acids to CLA. The CLA-producing bacterium is selected from one or more of the group consisting of propionibacteria, lactobacilli, lactococci and streptococci, and bifidobacteria.Type: ApplicationFiled: September 30, 2008Publication date: November 11, 2010Applicants: UNIVERSITY COLLEGE CORK, NATIONAL UNIVERSITY OF IRELAND, CORK, TEAGASC, The Agriculture and Food Development Authority, ALIMENTARY HEALTH LTD.Inventors: Liam O'Mahony, Fergus Shanahan, Eamonn Quigley, Paul Ross, Catherine Stanton
-
Publication number: 20100284980Abstract: A nutritional formula which includes a lipid or fat; a protein source; about 5 to about 100 mg/100 kcal of a source of long chain polyunsaturated fatty acids which comprises docosahexanoic acid; about 0.1 to about 1 mg/100 kcal of a prebiotic composition, wherein the prebiotic composition comprises at least 20% of an oligosaccharide which comprises galacto-oligosaccharide; and about 0.015 to about 0.1 (pg/?g) ppm of TGF-?.Type: ApplicationFiled: May 11, 2009Publication date: November 11, 2010Inventors: Francisco J. Rosales, Eric van Tol, Gyan P. Rai, Dirk Hondmann, Kirstin Morris, Dattatreya Banavara, Zeina E. Jouni, Robert J. McMahon, Deborah A. Schade, Donald Carey Walker
-
Patent number: 7829079Abstract: The present invention provides methods and compositions for administration of Lactobacillus iners alone or together with at least one other probiotic organism such as Bifordobacterium, or another Lactobacillus for reduction of the risk of urogenital infection and concomitant restoration and/or maintenance of a healthy urogenital flora. A method of treatment of vaginal infections is also contemplated.Type: GrantFiled: March 28, 2003Date of Patent: November 9, 2010Assignee: Christian Hansen A/SInventors: Gregor Reid, Jeremy Burton
-
Publication number: 20100278793Abstract: The present invention relates to the cosmetic treatment of greasy skin and/or skin that tends to be greasy with a lysate of at least one microorganism of the genus Bifidobacterium species and/or a fraction thereof, as an active.Type: ApplicationFiled: October 28, 2009Publication date: November 4, 2010Applicant: L'OREALInventors: Audrey Gueniche, Isabelle Castiel, Dominique Bernard
-
Publication number: 20100278794Abstract: An agent for promoting the secretion of adiponectin and/or suppressing decrease of adiponectin, a food or beverage for promoting the secretion of adiponectin and/or suppressing decrease of adiponectin, and a feed, each of which comprises a culture supernatant of Lactobacillus gasseri SBT2055 (FERM BP-10953) as an active ingredient.Type: ApplicationFiled: October 28, 2008Publication date: November 4, 2010Applicant: SNOW BRAND MILK PRODUCTS CO., LTD.Inventors: Yukiko Kunieda, Yasuyuki Seto, Yukio Kadooka
-
Publication number: 20100278795Abstract: An object of the present invention is to provide a useful composition that contains a highly safe lactic acid bacterium or a component derived from this lactic acid bacterium. The present invention relates to a composition comprising at least one lactic acid bacterium selected from the group consisting of Lactobacillus delbrueckii subsp. lactis strain KR-037 (NITE BP-395), Lactobacillus delbrueckii subsp. lactis strain KLAB-4 (NITE BP-394), and variants thereof, or comprising a component derived from the lactic acid bacterium. The composition of the present invention is useful as a preparation that has an excellent antiallergic function and also has at least one other function selected from an anti-autoimmune disease function, a diabetes-improving function, a neutral fat-lowering function, and so forth.Type: ApplicationFiled: November 19, 2008Publication date: November 4, 2010Applicant: Kaneka CorporationInventors: Airo Tategaki, Toyoki Watanabe, Kazuya Hamada
-
Publication number: 20100278796Abstract: The invention relates to a method for improving the digestibility and assimilability of fibres and/or cereals in a monogastric herbivorous animal comprising the step of administering to said monogastric herbivorous animal an effective amount of at least one strain of bacterium selected fromselected from the group consisting of strains of bacteria of the genera Lactobacillus, Lactococcus, Propionibacterium, Bifidobacterium and Bacillus. The invention also relates to a feed supplement for a monogastric herbivorous animal comprising at least one strain of bacterium selected fromselected from the group consisting of strains of bacteria of the genera Lactobacillus, Lactococcus, Propionibacterium, Bifidobacterium and Bacillus.Type: ApplicationFiled: April 22, 2010Publication date: November 4, 2010Applicant: DANISCO A/SInventor: Claudette Berger
-
Publication number: 20100266550Abstract: The present invention relates to a novel approach to prevent or treat mastitis both in humans and animals through the use of mammal milk-derived microorganisms obtained from healthy hosts of the homologous species; to those new probiotic microorganisms obtained from milk able to reduce infectious mastitis and the method of screening used for their obtaining; to the use of these probiotic bacteria for the prophylaxis or treatment against mastitis and other diseases; and finally, to compositions comprising these compounds.Type: ApplicationFiled: June 2, 2008Publication date: October 21, 2010Applicant: PULEVA BIOTECH, S.A.Inventors: Rocio Martín Jiménez, Monica Olivares Martín, Esther Antonia Jiménez Quintana, Maria Luisa Marín Martínez, Saleta Sierra Ávila, Antonio Maldonado Barragán, Virginia Martín Merino, Francesc Blanch Martell, Celina Torre Lloveras, Federico Villoslada, Reebeca Arroyo Rodríguez, Julio Boza Puerta, Jesús Jiménez López, Leónides Fernández Álvarez, Odón Julían Sobrino Abuja, Jordi Xaus Pei, Juan Miguel Rodríguez Gómez, Susana Delgado Palacio
-
Publication number: 20100266560Abstract: The invention relates to a composition and method of manufacture including a substrate coated with a biopolymer and aqueous biological gel and subsequently coated with at least one desiccation agent. The resulting composition is dry to touch, has a low water activity and stabilises the biological material for storage over at least one month at ambient temperatures.Type: ApplicationFiled: November 6, 2008Publication date: October 21, 2010Applicant: ENCOATE HOLDINGS LIMITEDInventors: Jayanthi Swaminathan, Trevor Anthony Jackson
-
Publication number: 20100254956Abstract: The present invention provides methods for manufacturing heat treated products involving the use of probiotic bacteria, e.g. lactic acid bacteria and/or Bifidobacteria, cultures of such bacteria, supernatant from such cultures, and/or concentrates of such supernatant and/or fractions of such supernatant. The invention further provides heat treated products of such processes and their use for regulation of cellular uptake of fat and/or triglycerides and/or body weight management or weight reduction and/or redistribution of fat and/or reduction in visceral and/or abdominal fat deposition in a subject.Type: ApplicationFiled: December 5, 2008Publication date: October 7, 2010Inventors: Velmurugesan Arulampalam, Joseph James Rafter, Sven Pettersson
-
Patent number: 7807151Abstract: The present invention discloses compositions and methodologies for the utilization of probiotic organisms in therapeutic compositions. More specifically, the present invention relates to the utilization of one or more species or strains of lactic acid-producing bacteria, preferably strains of Bacillus coagulans, for the control of gastrointestinal tract pathogens, including antibiotic-resistant gastrointestinal tract pathogens, and their associated diseases by both a reduction in the rate of colonization and the severity of the deleterious physiological effects of the colonization of the antibiotic-resistant pathogen. In addition, the present invention relates to the utilization of therapeutic compounds comprised of lactic acid-producing bacteria and anti-microbial agents such as antibiotics, anti-fungal compounds, anti-yeast compounds, or anti-viral compounds.Type: GrantFiled: April 23, 2008Date of Patent: October 5, 2010Assignee: Ganeden Biotech, IncorporatedInventor: Sean Farmer
-
Publication number: 20100247500Abstract: The survival of lactic acid bacterial strains such as probiotic bacteria contained in yogurt etc. is improved. A lactic acid bacterium survival improver including a propionic acid bacterium fermentation product to improve the survival of a lactic acid bacterium. The propionic acid bacterium is a bacterium belonging to the genus Propionibacterium. The bacterium belonging to the genus Propionibacterium is Propionibacterium freudenreichii.Type: ApplicationFiled: November 18, 2008Publication date: September 30, 2010Inventors: Kakuhei Isawa, Hideaki Uchida, Keisuke Furuichi, Fuyuko Yamamoto
-
Patent number: 7799551Abstract: Ferulate esterase producing bacterial strains or functional mutants thereof and methods of using ferulate esterase producing bacterial strains as forage additives are disclosed.Type: GrantFiled: September 1, 2005Date of Patent: September 21, 2010Assignee: Pioneer Hi-Bred International, Inc.Inventors: Victor Nsereko, William Rutherford, Brenda Smiley, Annette Spielbauer
-
Publication number: 20100226899Abstract: The present disclosure provides embodiments of a method for characterizing microbial populations. Exemplified by methods for characterizing microbiota in vaginal samples, the methods provided herein are widely applicable to the characterization of microbial communities. Also provided are probiotic regimens and methods for selecting appropriate probiotic regimens based on the normal vaginal microbiota of a subject. Reagents and kits for detecting normal vaginal microbiota and diagnosing pathogenic microorganisms in the vagina are also provided.Type: ApplicationFiled: October 23, 2009Publication date: September 9, 2010Applicants: Idaho Research Foundation, Procter & GambleInventors: Thomas Osborn, Catherine Davis, Bruce Johns, Larry J. Forney, James Foster, Celeste Brown, Paul Joyce, Zaid Abdo, Audra Johnson, Xia Zhou
-
Publication number: 20100226995Abstract: The presently claimed and disclosed inventive concept(s) contemplates a novel polymeric oral dosage form (transmucosal delivery vehicle) for delivery of pharmaceutical and nutriceutical bioactive agents to the mucosa and bloodstream of the intestine. The oral dosage form of the presently claimed and disclosed inventive concept(s) comprises a polymeric coating which encapsulates the bioactive agent and inhibits degradation and dissolution of the bioactive agent within the stomach and within the lumen of the intestine until after passing through the mucosal wall of the small and/or large intestine. The enzymatic degradation of the polymeric delivery vehicle containing the bioactive agent is substantially inhibited until after absorption of the polymeric delivery vehicle into blood vessels of the intestinal mucosa.Type: ApplicationFiled: March 5, 2010Publication date: September 9, 2010Inventor: Daniel R. DeBrouse